<DOC>
	<DOCNO>NCT00003666</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient relapsed refractory non-small cell lung cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Relapsed Refractory Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate 6-hydroxymethylacylfulvene ( HMAF ) salvage chemotherapy patient relapse refractory non-small cell lung cancer . II . Determine duration response regimen patient population . III . Determine effect prior response chemotherapy response HMAF patient . IV . Determine survival failure-free survival patient treat HMAF . V. Evaluate toxicity profile HMAF salvage therapy patient . OUTLINE : Patients stratify relapsed refractory patient group base result achieve prior therapy . Patients receive 6-hydroxymethylacylfulvene IV 5 minute daily 5 day . Courses repeat every 28 day . Patients stable respond disease treat minimum 6 course ( 2 course beyond optimal response ) absence unacceptable toxic effect disease progression . Patients follow least every 3 month 1 year , every 6 month death . PROJECTED ACCRUAL : A total 66 patient ( 33 stratum ) accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven recurrent refractory nonsmall cell lung cancer Squamous cell Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic ( giant clear cell carcinoma ) Measurable disease ( bone disease , pleural pericardial effusion , irradiated lesion , unless progression document radiotherapy ) No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal ( ULN ) Renal : Creatinine great ULN Cardiovascular : No active cardiac disease No unstable angina No myocardial infarction within 6 month No congestive heart failure No inability tolerate hypotension Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No uncontrolled diabetes mellitus No psychiatric disorder No concurrent secondary malignancy except nonmelanomatous skin cancer patient less 30 % risk relapse PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since mitomycin ) At least 1 prior chemotherapy agent combination , include adjuvant neoadjuvant therapy nonsmall cell lung cancer No 1 prior chemotherapy agent combination metastatic recurrent disease No prior HMAF No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except nondisease related condition Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent palliative radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>